Bispecific Antibody Improves NK Cell Response Rate in Lymphoma Patients
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
[New Cell Therapy for Malignant Lymphoma] A novel cell therapy combines cord blood-derived natural killer (NK) cells with the CD30/CD16A bispecific antibody AFM13 (acimtamig), offering a safe and highly effective treatment option for patients with refractory CD30-positive lymphoma.
Key Data:
- This therapy demonstrates a strong response rate in patients with refractory CD30-positive lymphoma.
- The incidence of side effects during treatment is relatively low, providing a safer therapeutic environment.
- Quality of life for patients significantly improved following treatment.
For more details, please visit: https://tinyurl.com/26wa84x3
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1